Scarica l'app Stockscreener
4.82
1.63%
-0.08
Dopo l'orario di chiusura:
4.84
0.02
+0.41%
Precedente Chiudi:
$4.90
Aprire:
$4.85
Volume 24 ore:
13,228
Relative Volume:
0.22
Capitalizzazione di mercato:
$27.60M
Reddito:
$257.00K
Utile/perdita netta:
$-3.07M
Rapporto P/E:
-5.0593
EPS:
-0.9527
Flusso di cassa netto:
$-1.40M
1 W Prestazione:
-2.63%
1M Prestazione:
-1.63%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.7801
$4.99
Intervallo di 1 settimana:
$4.75
$5.15
Portata 52W:
$4.00
$6.20
Optimi Health Corp Stock (OPTH) Company Profile
Compare OPTH vs TAK, TEVA, HLN, ZTS, VTRS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OPTH
Optimi Health Corp
|
4.82 | 27.60M | 257.00K | -3.07M | -1.40M | -0.9527 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Optimi Health Corp Borsa (OPTH) Ultime notizie
Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial - Mugglehead Investment Magazine
Optimi Health Completes Psilocybin Production for Phase 2 MDD Trial - marketscreener.com
Optimi completes psilocybin capsule batch for trial, Australia - Investing.com Australia
Optimi completes psilocybin capsule batch for trial, Australia By Investing.com - Investing.com UK
Optimi Health Completes Psilocybin Production for Health - GlobeNewswire
Optimi Health Corp. (OPTI.CN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer to Advance Psilocybin and MDMA Trials - kalkine.ca
Optimi Health Appoints Dr Michael Blough to Head Clinical Development - Yahoo Finance
Optimi Health appoints Michael Blough as clinical officer - Investing.com
Optimi Health Corp. Appoints Michael Blough as Chief Clinical Development Officer to Advance Psychedelic Clinical Trials - Quiver Quantitative
Psychedelic depression and PTSD trials get new lead at Optimi Health (OPTH) - stocktitan.net
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer - Yahoo Finance
Optimi Health Corp. Common Shares (NASDAQ: OPTH) Stock Price, News & Analysis - kalkine.com.au
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial - Yahoo Finance
Optimi Health2026 Funding Rounds & List of Investors - Tracxn
Optimi Health Stock Slips 4.17%: Controlled Substances Commercialization Friction and Sector Volatility Weigh on Sentiment - kalkine.ca
Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA T - Benzinga
SRx Health Decided To Invest In A Psychedelic Drug Company That Just Went Public – Here’s What Aided The Decision - Stocktwits
Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder - Investing News Network
Optimi Health plans phase 3 MDMA trial for PTSD in Canada - Investing.com Australia
Optimi Health Launches Phase 3 MDMA-Assisted Therapy Trial for PTSD Targeting Veterans and Frontline Workers - kalkine.ca
Optimi Health (OPTH) lines up Phase 3 MDMA PTSD trial for veterans - Stock Titan
Optimi Health (OPTI.CN) Launches Health Canada-Authorized Phase 3 MDMA Trial for PTSD in Veterans and Frontline Workers - kalkine.ca
Optimi Health (OPTH) Stock Price, News & Analysis - Stock Titan
3 Small Cap Stocks With Strong Revenue Growth And Low Debt - Yahoo Finance
Optimi Health Corp. (CN:OPTI) Gains Momentum as Psychedelic Medicine Expansion and Clinical Progress Improve Investor Outlook - kalkine.ca
Optimi Health Corp Share PriceOPTI, RNS News, Articles, Quotes, & Charts (CNSX:OPTI) - Proactive financial news
OPTI: Commercially supplying natural psychedelics, expanding globally as regulations advance - TradingView
Optimi Health at H.C. Wainwright conference: early lead in psychedelics - Investing.com
OPTI: Commercial psychedelic manufacturer expands globally as regulatory momentum accelerates - TradingView
Optimi Health Corp. (CN:OPTI) Advances as Psychedelic Medicine Pipeline and Clinical Expansion Improve Investor Sentiment - kalkine.ca
Optimi Health plans phase 2 psilocybin trial for depression By Investing.com - Investing.com Nigeria
OPTH Stock Price, Quote & News - Syfe
OPTH Looks 64.2% Overvalued on GF Value™ - GuruFocus
Optimi Health Launches Health Canada-Authorized Phase 2 Psilocybin Trial for Major Depressive Disorder - kalkine.ca
Optimi Health To Initiate Phase 2 Psilocybin Trial For Major Depression - RTTNews
Optimi Health plans phase 2 psilocybin trial for depression - Investing.com
Optimi Health CorpTrial Initiation Planned For H1 2027, Dosing To Complete By End Of 2027 - TradingView
Optimi Health Announces Health Canada-Authorized Phase 2 Trial of Natural Psilocybin for Major Depressive Disorder - Quiver Quantitative
A 200-person psilocybin depression trial is coming from Optimi Health (OPTH); here’s when and where - Stock Titan
Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder - Yahoo Finance
Optimi Health Stock Under Pressure: Can Psychedelic Growth Overcome Rising Execution and Funding Risks? - kalkine.ca
symbol__ Stock Quote Price and Forecast - CNN
Optimi Health to Present at H.C. Wainwright Global Investment Conference - TipRanks
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Optimi Health Corp. to Present at H.C. Wainwright 28th Annual Global Investment Conference in September 2026 - kalkine.ca
Psychedelic-drug maker Optimi Health (OPTH) plans investor meetings in New York - Stock Titan
Optimi Health Stock Faces Renewed Pressure as Psychedelic-Sector Sentiment Weakens - kalkine.ca
Optimi Health (CN:OPTI) Drops 4.12% as Revenue Weakness, Funding Risk and Psychedelic-Sector Uncertainty Pressure Sentiment - kalkine.ca
Optimi Health Corp (CN: OPTI) Share Price, OPTI Stock News, OPTI Share Price & Updates - kalkine.ca
Optimi Health (OPTH) lines up discounted share funding with new $100M facility - Stock Titan
Optimi Health Corp Azioni (OPTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.18%
0.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):